Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Twist Bioscience Corporation - Common Stock (NQ: TWST )

54.07 +0.77 (+1.44%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Twist Bioscience Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Twist Bioscience to Report Fiscal 2024 First Quarter Financial Results on Friday, February 2, 2024
From Twist Bioscience Corporation
Via Business Wire
Biotech Playbook: Small Caps Show Momentum Peaking During
The momentum of selected stocks was strong up until early January was encouraging but we need less volatility in period ahead to conform a new bull market. 
Via Talk Markets
Twist Bioscience Corporation Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Corp. (NASDAQ: TWST) Near the Top of Equities by Percentage Gain on 11/17
Via Investor Brand Network
Twist Bioscience: Q4 Earnings Insights
Via Benzinga
Twist Bioscience Appoints Adam Laponis as Chief Financial Officer
From Twist Bioscience Corporation
Via Business Wire
3 Genomics Stocks to Unlock the Future of Medicine
Genomics stocks stand to surge in 2024 after the FDA approved the nation's first gene-editing therapeutic for clinical use. 
Via InvestorPlace
Exposures Product Safety
Twist Bioscience to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Twist Bioscience Corporation
Via Business Wire
Tuesday Talk: CPI Data And FOMC Meeting Hold Back Market Breakout
While the market continues towards making new highs, it is falling short of making a breakout rally. Forthcoming CPI data and the upcoming FOMC meeting may be the catalyst for same. 
Via Talk Markets
Biotech Is Coming Back, Can The Run Last?
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally. 
Via Talk Markets
Five Best Performing Stocks Of The Top ETF Of November
Most stocks in ARKK’s portfolio delivered strong returns in November. These five led the way. 
Via Talk Markets
Topics ETFs
Cramer Says No To This EV Maker, But Recommends This Major Automaker Stock: It 'Goes Up And Up'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said no to Lucid Group, Inc. 
Via Benzinga
S&P 500 Edges Higher; Buckle Shares Surge After Q3 Earnings
U.S. stocks traded slightly higher toward the end of trading, with the Nasdaq Composite gaining around 30 points on Friday. The Dow traded up 0.07% to 34,969.63 while the NASDAQ rose 0.21% to... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Dolby Laboratories Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Dolby Laboratories, Inc. (NYSE: DLB) fell during Friday’s session following weak guidance. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Crude Oil Rises Over 3%; BJ's Wholesale Posts Weak Sales
U.S. stocks traded mostly flat midway through trading on Friday. The Dow traded up 0.01% to 34,945.78 while the NASDAQ fell 0.03% to 14,109.53. The S&P 500 also rose, gaining, 0.05% to 4,510.71. 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mostly lower, with the Dow Jones falling over 20 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
DNA-Maker Twist Bioscience Catapults 21% As 'Solid' Outlook That Tops Its Peers
The company expects sales to grow 16% to 18% in fiscal year 2024, which is already underway. 
Via Investor's Business Daily
Why Synthetic DNA Company Twist Bioscience Shares Are Jumping Today
Twist Bioscience Corp's (NASDAQ: TWST) Q4 sales increased 16.8% Y/Y to $66.9 million,  
Via Benzinga
Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2023 Financial Results
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Launches Express Genes Rapid Gene Synthesis Service
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Present at 6th Annual Evercore ISI HealthCONx Conference
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Report Fiscal 2023 Fourth Quarter and Full Year Financial Results on Friday, November 17, 2023
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Launches Full Length Unique Dual Index Adapters to Enable PCR-free Whole Genome Sequencing
From Twist Bioscience Corporation
Via Business Wire
TWIST ALERT: Bragar Eagel & Squire, P.C. is Investigating Twist Bioscience Corp on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Twist Bioscience Enters into Antibody Discovery and Licensing Option Agreement with Bayer of up to $188 Million
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Appoints Mark Buck as Senior Vice President, Operations
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience and IMIDomics Collaborate to Discover Antibodies for Applications in Immune-Mediated Inflammatory Diseases
From Twist Bioscience Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.